Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc. (XBIO): 3 pipeline candidates · ~42 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
41.5 months
D/E 0.14 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Xenetic Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.9M
Cash
$7.3M
Quarterly Burn
$536K
Runway
41.5 mo
Revenue
$807K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| dnase-armored car t | Preclinical |
| erepoxen | Phase 2 |
| iv rhdnase i | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$462K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 137,440 | $368K |
| geode capital management, llc | 21,441 | $57K |
| vanguard capital management llc | 13,462 | $36K |
| jtc employer solutions trustee ltd | 2,700 | $7 |
Frequently asked questions
How many drug candidates are in Xenetic Biosciences, Inc.'s pipeline?
Xenetic Biosciences, Inc. (XBIO) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Xenetic Biosciences, Inc.'s lead drug candidate?
Xenetic Biosciences, Inc.'s most advanced tracked candidate is dnase-armored car t (Preclinical) for solid tumors.
What is Xenetic Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Xenetic Biosciences, Inc. has approximately 41.5 months of cash runway.
What is Xenetic Biosciences, Inc.'s market capitalization?
Xenetic Biosciences, Inc.'s market capitalization is approximately $6.9M.
Who is the CEO of Xenetic Biosciences, Inc.?
Mr. James F. Parslow is the chief executive officer of Xenetic Biosciences, Inc. (XBIO).
Get the full picture on Xenetic Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.